Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

859762.pdf (751.63 KB)

Document type

Article

Version

Accepted version

Publication date

2024-02-29

All rights reserved

Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/216582

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1038/s41571-024-00868-0

Abstract

Liver cancer, specifically hepatocellular carcinoma (HCC), is the sixth most common cancer and the third leading cause of cancer mortality worldwide. The development of effective systemic therapies, particularly those involving immune-checkpoint inhibitors (ICIs), has substantially improved the outcomes of patients with advanced-stage HCC. Approximately 30% of patients are diagnosed with early stage disease and currently receive potentially curative therapies, such as resection, liver transplantation or local ablation, which result in median overall survival durations beyond 60 months. Nonetheless, up to 70% of these patients will have disease recurrence within 5 years of resection or local ablation. To date, the results of randomized clinical trials testing adjuvant therapy in patients with HCC have been negative. This major unmet need has been addressed with the IMbrave 050 trial, demonstrating a recurrence-free survival benefit in patients with a high risk of relapse after resection or local ablation who received adjuvant atezolizumab plus bevacizumab. In parallel, studies testing neoadjuvant ICIs alone or in combination in patients with early stage disease have also reported efficacy. In this Review, we provide a comprehensive overview of the current approaches to manage patients with early stage HCC. We also describe the tumour immune microenvironment and the mechanisms of action of ICIs and cancer vaccines in this setting. Finally, we summarize the available evidence from phase II/III trials of neoadjuvant and adjuvant approaches and discuss emerging clinical trials, identification of biomarkers and clinical trial design considerations for future studies.

Subject

Càncer de fetge, Immunoteràpia, Adjuvants immunològics, Assaigs clínics

Subject (English)

Liver cancer, Immunotheraphy, Immunological adjuvants, Clinical trials

Citation

Collections

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citation

LLOVET I BAYER, Josep Maria, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nature Reviews Clinical Oncology. 2024. Vol. 21, num. 4, pags. 294-311. ISSN 1759-4774. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/216582

Export metadata

JSON - METS

Share record